Cargando…
Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study
AIM: To assess the impact of baseline characteristics on Men's Sexual Health Questionnaire (MSHQ) total scores and to evaluate the clinical relevance of MSHQ changes and their association with spontaneously reported sexual adverse events (SexAEs) in patients with benign prostatic hyperplasia. M...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187250/ https://www.ncbi.nlm.nih.gov/pubmed/31927774 http://dx.doi.org/10.1111/ijcp.13480 |
_version_ | 1783527135468584960 |
---|---|
author | Roehrborn, Claus G. Rosen, Raymond C. Manyak, Michael J. Palacios‐Moreno, Juan Manuel Wilson, Timothy H. Lulic, Zrinka Giuliano, François |
author_facet | Roehrborn, Claus G. Rosen, Raymond C. Manyak, Michael J. Palacios‐Moreno, Juan Manuel Wilson, Timothy H. Lulic, Zrinka Giuliano, François |
author_sort | Roehrborn, Claus G. |
collection | PubMed |
description | AIM: To assess the impact of baseline characteristics on Men's Sexual Health Questionnaire (MSHQ) total scores and to evaluate the clinical relevance of MSHQ changes and their association with spontaneously reported sexual adverse events (SexAEs) in patients with benign prostatic hyperplasia. METHODS: This was a post hoc analysis of the Phase 4 FDC116115 study, in which patients aged ≥50 years were randomised 1:1 to receive a fixed‐dose combination of dutasteride 0.5 mg and tamsulosin 0.4 mg (DUT‐TAM FDC), or placebo. End‐points included: change in MSHQ total scores by baseline characteristics and SexAEs; cumulative distribution function for change from baseline to month 12 in MSHQ total score and the ejaculation, erection, satisfaction and sexual desire (libido) domain scores; and relationship between changes in MSHQ scores and SexAEs. RESULTS: The intent‐to‐treat population comprised 489 patients (DUT‐TAM FDC, n = 243; placebo, n = 246). The mean reduction in total MSHQ score was greater in patients with SexAEs across both groups, compared with patients without SexAEs. Most patients reporting any SexAE (86% DUT‐TAM FDC, 67% placebo) had a worsening of the MSHQ total score at month 12 compared with baseline. Specifically, 90% (DUT‐TAM FDC) and 75% (placebo) of patients reporting an ejaculation SexAE and 73% (DUT‐TAM FDC) and 87% (placebo) of patients reporting an erection SexAE had a worsening of MSHQ ejaculation and erection domain scores, respectively, at month 12. A threshold effect for incident SexAE was observed; patients showing a decrease of approximately 6‐10 points in the total MSHQ score were more likely to report SexAEs. CONCLUSION: Findings support the clinical utility of the MSHQ tool in assessing the impact of DUT‐TAM on sexual function by linking numerical changes in MSHQ scores to spontaneously reported SexAEs for the first time. The threshold effect for incidence of SexAEs warrants further investigation to determine its clinical relevance. |
format | Online Article Text |
id | pubmed-7187250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71872502020-04-28 Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study Roehrborn, Claus G. Rosen, Raymond C. Manyak, Michael J. Palacios‐Moreno, Juan Manuel Wilson, Timothy H. Lulic, Zrinka Giuliano, François Int J Clin Pract Original Papers ‐ Men's Health AIM: To assess the impact of baseline characteristics on Men's Sexual Health Questionnaire (MSHQ) total scores and to evaluate the clinical relevance of MSHQ changes and their association with spontaneously reported sexual adverse events (SexAEs) in patients with benign prostatic hyperplasia. METHODS: This was a post hoc analysis of the Phase 4 FDC116115 study, in which patients aged ≥50 years were randomised 1:1 to receive a fixed‐dose combination of dutasteride 0.5 mg and tamsulosin 0.4 mg (DUT‐TAM FDC), or placebo. End‐points included: change in MSHQ total scores by baseline characteristics and SexAEs; cumulative distribution function for change from baseline to month 12 in MSHQ total score and the ejaculation, erection, satisfaction and sexual desire (libido) domain scores; and relationship between changes in MSHQ scores and SexAEs. RESULTS: The intent‐to‐treat population comprised 489 patients (DUT‐TAM FDC, n = 243; placebo, n = 246). The mean reduction in total MSHQ score was greater in patients with SexAEs across both groups, compared with patients without SexAEs. Most patients reporting any SexAE (86% DUT‐TAM FDC, 67% placebo) had a worsening of the MSHQ total score at month 12 compared with baseline. Specifically, 90% (DUT‐TAM FDC) and 75% (placebo) of patients reporting an ejaculation SexAE and 73% (DUT‐TAM FDC) and 87% (placebo) of patients reporting an erection SexAE had a worsening of MSHQ ejaculation and erection domain scores, respectively, at month 12. A threshold effect for incident SexAE was observed; patients showing a decrease of approximately 6‐10 points in the total MSHQ score were more likely to report SexAEs. CONCLUSION: Findings support the clinical utility of the MSHQ tool in assessing the impact of DUT‐TAM on sexual function by linking numerical changes in MSHQ scores to spontaneously reported SexAEs for the first time. The threshold effect for incidence of SexAEs warrants further investigation to determine its clinical relevance. John Wiley and Sons Inc. 2020-02-11 2020-05 /pmc/articles/PMC7187250/ /pubmed/31927774 http://dx.doi.org/10.1111/ijcp.13480 Text en © 2020 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Papers ‐ Men's Health Roehrborn, Claus G. Rosen, Raymond C. Manyak, Michael J. Palacios‐Moreno, Juan Manuel Wilson, Timothy H. Lulic, Zrinka Giuliano, François Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study |
title | Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study |
title_full | Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study |
title_fullStr | Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study |
title_full_unstemmed | Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study |
title_short | Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study |
title_sort | men’s sexual health questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a post hoc analysis of a prospective, randomised, placebo‐controlled study |
topic | Original Papers ‐ Men's Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187250/ https://www.ncbi.nlm.nih.gov/pubmed/31927774 http://dx.doi.org/10.1111/ijcp.13480 |
work_keys_str_mv | AT roehrbornclausg menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol AT rosenraymondc menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol AT manyakmichaelj menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol AT palaciosmorenojuanmanuel menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol AT wilsontimothyh menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol AT luliczrinka menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol AT giulianofrancois menssexualhealthquestionnairescorechangesvsspontaneoussexualadverseeventreportinginmentreatedwithdutasteridetamsulosincombinationtherapyforlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaaposthocanalysisofaprospectiverandomisedplacebocontrol |